To include your compound in the COVID-19 Resource Center, submit it here.

KUR-113: Phase IIb data

An open-label, European Phase IIb trial in open tibial shaft fracture patients showed that 0.4 mg/mL KUR-113 plus standard of care (SOC) met the primary endpoint of a significantly

Read the full 296 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE